Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH) clarified market rumors about cryptocurrency exposure on February 5, 2026. The company said it holds no cryptocurrency assets and that its maximum exposure over the last year "never reached more than $350,000 USD."
Hoth also reaffirmed ongoing work on the HT-001 clinical trial and progress toward additional oncology and obesity studies.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
HOTH was down 4.33% while the only peer in the momentum scan (CTXR) was up 6.17%, and broader biotech peers showed mixed moves, indicating stock-specific factors rather than a sector-wide crypto-driven move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 22 | Interim trial data | Positive | +0.0% | Positive interim HT-001 CLEER-001 data with improved ARIGA and pruritus scores. |
| Jan 21 | Patent approval | Positive | -1.9% | China patent approval for HT-KIT cancer program expanding oncology IP in major market. |
| Jan 15 | IRB approvals | Positive | +3.4% | IRB approvals for Phase 2a HT-001 trial and disclosure of over $9M cash and no 2024 raises. |
| Jan 15 | EU regulatory step | Positive | +3.4% | Positive EU CTIS Part I conclusion enabling multi-country HT-001 site activation. |
| Jan 02 | Patent filings | Positive | +8.1% | Two U.S. provisional patents extending HT-001 use across oncology skin toxicities. |
Recent oncology and IP milestones for HOTH have generally seen positive or flat next-day moves, with only one modest negative reaction, suggesting constructive responses to clinical and patent news.
Over the past month, HOTH has focused on oncology and supportive-care dermatology. On Jan 2, it filed two U.S. provisional patents to build an oncology dermatology IP platform. On Jan 15, it secured IRB approvals for a Phase 2a HT-001 trial and received a positive EU CTIS Part I conclusion, both followed by +3.35% to +8.08% moves. A Chinese HT-KIT patent on Jan 21 saw a -1.87% reaction, while interim HT-001 data on Jan 22 had a flat move. Today’s crypto clarification sits against this backdrop of clinical and IP progress.
Regulatory & Risk Context
An effective Form S-3 shelf filed on Nov 14, 2025 allows Hoth to offer up to $50 million of various securities and register 1,279,587 resale shares, providing financing flexibility that could lead to future equity or debt issuance.
Market Pulse Summary
This announcement addressed market rumors by stating that Hoth holds no cryptocurrency assets and that its maximum digital asset exposure over the last year never exceeded $350,000. The company also reiterated ongoing execution of its HT-001 clinical trial and advancement of its oncology and obesity pipeline. In recent months, Hoth has reported multiple clinical, regulatory, and IP milestones, alongside an effective $50 million shelf registration that provides financing flexibility for future development.
AI-generated analysis. Not financial advice.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-addresses-market-rumor-hoth-holds-no-crypto-currency-assets-302680194.html
SOURCE Hoth Therapeutics, Inc.
FAQ
Does Hoth Therapeutics (HOTH) hold any cryptocurrency assets as of February 5, 2026?
What was Hoth Therapeutics' maximum cryptocurrency exposure reported on February 5, 2026?
How does Hoth Therapeutics' crypto disclosure affect HOTH shareholders on February 5, 2026?
Is Hoth Therapeutics continuing its HT-001 clinical trial after the February 5, 2026 statement?
Where can investors find official statements about Hoth Therapeutics' cryptocurrency exposure (HOTH)?
